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Symptom research with advanced lung cancer patients has primarily focused on symptom 
severity, frequency, and distress; yet, little is known about advanced lung cancer patients’ 
priorities and success criteria for symptom improvement.  To address these gaps in the literature, 
this study examined these outcomes using a modified Patient Centered Outcomes Questionnaire 
(PCOQ), which has largely been used with adults with chronic pain.  Advanced lung cancer 
patients (N = 102) were recruited from the Indiana University Simon Cancer Center to participate 
in a one-time self-report survey, including demographic and medical questionnaires, symptom 
treatment history, standardized measures of symptom severity and quality of life, and the 
modified PCOQ focused on eight common symptoms in advanced lung cancer.  Cancer 
information was collected from medical records.  My primary aim was to evaluate the construct 
validity of the PCOQ.  As hypothesized, symptom severity ratings on the PCOQ were positively 
correlated with standardized assessments of the same symptoms as well as functional status.  
Greater severity of most symptoms on the PCOQ was also correlated with worse quality of life, 
and greater severity of four symptoms was correlated with having more medical comorbidities.  
Positive, moderate correlations were found between the severity and importance of seeing 
improvement in cough, fatigue, sleep problems, and pain on the PCOQ.  Patients considered low 
levels of symptom severity to be acceptable following symptom treatment; no differences were 
found across the eight symptoms.  Latent profile analysis identified four patient subgroups based 
on the importance of seeing improvement in each of the symptoms: (1) those who rated all 
symptoms as low in importance (n = 12); (2) those who rated bronchial symptoms and sleep 
problems as low in importance and all other symptoms as moderately important (n = 29); (3) 
those who rated nausea and emotional distress as low in importance and all other symptoms as 
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moderately important (n = 23); and (4) those who rated all symptoms as highly important (n = 
33).  These subgroups were unrelated to demographic and clinical factors, except for functional 
status.  Findings suggest that symptom severity and importance are related yet distinct aspects of 
the advanced lung cancer symptom experience.  Furthermore, patients have heterogeneous 




CHAPTER 1. INTRODUCTION 
Cancer symptom research has largely focused on symptom severity, frequency, and 
distress (Reeve et al., 2014).  This literature suggests that advanced lung cancer patients are more 
likely to experience high symptom burden than patients with other cancer types (Shi et al., 2011).  
However, little is known about advanced lung cancer patients’ success criteria for symptom 
improvement (i.e., acceptable symptom severity) and symptom management priorities.  
Understanding patients’ perspectives in these domains is critical for patient-centered care, which 
has been associated with improved patient satisfaction with health care, health outcomes, 
treatment adherence, and efficiency of care (Joosten et al., 2008; McMillan et al., 2013; Rathert, 
Wyrwich, & Boren, 2013; J. H. Robinson, Callister, Berry, & Dearing, 2008). 
 Patient-centered care encompasses three core values: considering patients’ needs, values, 
and preferences; providing patients with opportunities to participate in their care; and enhancing 
the patient-clinician relationship (Epstein, Fiscella, Lesser, & Stange, 2010).  One aspect of 
patient-centered care is shared decision making in which the clinician describes treatment 
options, including their risks and benefits, and the patient shares his or her preferences and 
values related to these options (Barry & Edgman-Levitan, 2012).  Thus, patients are empowered 
to actively participate in medical decision making and symptom management (te Boveldt et al., 
2014).  Patient-defined success criteria for symptom improvement inform shared treatment 
decisions by providing indices of clinically meaningful improvement from the patients’ 
perspective.  In addition, given that lung cancer patients have, on average, 14 symptoms (Choi & 
Ryu, 2018; Wong et al., 2017), assessing their priorities for symptom improvement is also 
critical for shared decision making. 
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 Success criteria and priorities for symptom improvement have been assessed with the 
Patient Centered Outcomes Questionnaire (PCOQ) in non-cancer populations, such as patients 
with chronic pain, Parkinson’s disease, fibromyalgia, or upcoming liver transplantation (Brown 
et al., 2008; Im Yi, Kim, Ha, & Lim, 2014; Nisenzon et al., 2011; O'Brien et al., 2010; M. E. 
Robinson et al., 2005; Rodrigue, Hanto, & Curry, 2011; Sanderson et al., 2012; Stutts et al., 
2009; Zeppieri, Bialosky, & George, 2020; Zeppieri et al., 2012).  The PCOQ (M. E. Robinson et 
al., 2005) measures patients’ usual symptom levels, desired or ideal symptom levels, successful 
symptom levels following symptom treatment, expected symptom levels following symptom 
treatment, and the importance of seeing improvement in each symptom.  The PCOQ assesses 
these domains for each of the following outcomes: pain, fatigue, emotional distress, and 
symptom interference with daily activities.  
Research using the PCOQ has found differences across medical populations in the level 
of symptom reduction considered a treatment success.  Patients with various types of chronic 
pain required a 56-75% reduction in pain, 57-71% reduction in fatigue, 52-77% reduction in 
emotional distress, and a 66-80% reduction in symptom interference with daily activities to 
consider symptom treatment successful (Im Yi et al., 2014; M. E. Robinson et al., 2005; Zeppieri 
et al., 2012).  Similarly, fibromyalgia patients required 54-63% reductions in pain, fatigue, 
emotional distress, and symptom interference to consider treatment successful (O'Brien et al., 
2010).  Other medical populations had lower criteria for treatment success.  For example, people 
awaiting liver transplant required 33-56% reductions in the same symptom domains to consider 
their transplantation successful (Rodrigue et al., 2011), and those with Parkinson’s disease 
required 40-52% reductions in these domains (Nisenzon et al., 2011).  
 
11 
Furthermore, subgroups of patients with chronic pain have been identified based on their 
symptom improvement priorities on the PCOQ.  Robinson et al. (2005) found three patient 
subgroups with: 1) high importance in all domains (i.e., multi-focused high importance), 2) 
moderate importance in all domains (i.e., multi-focused moderate importance), and 3) low 
importance in all domains except for pain (i.e., pain-focused importance).  The multi-focused 
high importance subgroup was significantly older and had higher usual levels of fatigue, distress, 
and symptom interference with daily activities than the other two groups.  The multi-focused 
high importance group also had higher usual levels of pain than the multi-focused moderate 
importance group.  These findings were partially replicated in another study of patients with 
chronic pain (Im Yi et al., 2014).  Specifically, the following subgroups were identified using the 
PCOQ: 1) high importance in all domains (i.e., pain, fatigue, distress, and symptom interference 
with daily activities), 2) moderate importance in all domains except for high pain importance, 
and 3) low importance in all domains except for high pain importance.  The patient subgroup 
with high importance in all domains had significantly greater depressive symptoms and anxiety 
than the other subgroups (Im Yi et al., 2014).  A third study of patients with chronic pain found 
only two patient clusters based on symptom importance ratings: 1) multi-focused high 
importance and 2) pain-focused importance; these subgroups did not differ on any clinical or 
demographic variables (Zeppieri et al., 2012).  These results were partially replicated in a fourth 
study of adults with musculoskeletal pain (Zeppieri et al., 2020).  Three subgroups were found 
using the PCOQ: 1) multi-focused high importance, 2) importance of pain and functional 
outcomes, and 3) pain-focused importance.  These subgroups differed with respect to pain, 
depressive symptoms, and anxiety, with the multi-focused high importance subgroup reporting 
greater pain than the other two subgroups, greater depressive symptoms than the subgroup 
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focused on pain and functional outcomes, and greater anxiety than the pain importance subgroup 
(Zeppieri et al., 2020). 
 To date, only one study has examined cancer patients’ success criteria for symptom 
improvement and symptom management priorities (Tometich et al., 2018).  For this study, the 
PCOQ was modified to include 10 common symptoms in metastatic breast cancer patients.  The 
sample rated fatigue, cognitive problems, and sleep problems as their most severe symptoms, 
although these ratings were in the moderate severity range.  In addition, patients required a 
significantly greater reduction in fatigue (49%) than all other symptoms except for cognitive 
problems (48%) and sleep problems (43%) to consider symptom treatment successful (Tometich 
et al., 2018).  The following subgroups based on priorities for symptom improvement also were 
found: 1) patients who rated cognitive problems, sleep problems, and fatigue as highly important, 
2) patients who rated pain as highly important, and 3) patients who rated all symptoms as highly 
important.  Few differences in demographic, medical, and symptom severity variables were 
found across subgroups.  Subgroup 1 reported higher education levels than subgroup 2 and 
higher levels of cognitive problems than subgroups 2 and 3.  
 It is important to expand research on success criteria for symptom improvement and 
symptom treatment priorities to other cancer populations with high symptom burden.  In 
particular, advanced lung cancer patients often experience various symptoms that are a major 
source of distress, impairment, and disability (Cooley, 2000; Iyer, Roughley, Rider, & Taylor-
Stokes, 2014; Shin et al., 2014; Tanaka, Akechi, Okuyama, Nishiwaki, & Uchitomi, 2002).  A 
greater percentage of lung cancer patients report moderate to severe fatigue/tiredness, disturbed 
sleep, pain, shortness of breath, dry mouth, lack of appetite, nausea, constipation, and emotional 
distress compared to patients with other cancer diagnoses (Cleeland et al., 2013; Dudgeon, 
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Kristjanson, Sloan, Lertzman, & Clement, 2001; Linden, Vodermaier, MacKenzie, & Greig, 
2012; Zabora, BrintzenhofeSzoc, Curbow, Hooker, & Piantadosi, 2001).  Regarding advanced 
lung cancer patients, the majority experience at least mild levels of lack of appetite (81-88%), 
fatigue (79-96%), sleep problems (79%), cough (77-84%), breathlessness (76-82%), emotional 
distress (73-89%), pain (58-77%), and nausea (43-69%) (Alt-Epping et al., 2012; Choi & Ryu, 
2018; Walling et al., 2015).  Fatigue, pain, breathlessness, and lack of appetite are among the 
most severe symptoms in advanced lung cancer (Iyer, Taylor-Stokes, & Roughley, 2013; Lee, 
Oh, Kim, & Kim, 2019).  Increased symptom severity has been associated with decrements in 
lung cancer patients’ functional status and quality of life (Akin, Can, Aydiner, Ozdilli, & Durna, 
2010). 
Symptom clusters in advanced lung cancer patients have also been identified.  One study 
found the following three symptom clusters in patients with inoperable lung cancer: a pain 
cluster consisting of pain, nausea, bowel issues, appetite loss, and fatigue; a mood cluster 
consisting of mood, outlook, concentration, and insomnia; and a respiratory cluster consisting of 
breathing difficulties and cough (Henoch, Ploner, & Tishelman, 2009).  Another study found 
three different symptom clusters in advanced lung cancer patients: a treatment symptom cluster 
consisting of nausea, vomiting, disturbed sleep, pain, and lack of appetite; a lung symptom 
cluster consisting of sore throat, breathlessness, cough, constipation, dry mouth, and drowsiness; 
and a psychoneurological symptom cluster consisting of distress, sadness, forgetfulness, fatigue, 
and numbness/tingling in hands and feet (Choi & Ryu, 2018).  Symptom clusters have been 
associated with reduced quality of life in lung cancer patients (Fox & Lyon, 2006).  
Although the high symptom burden of advanced lung cancer has been well documented 
(Alt-Epping et al., 2012; Choi & Ryu, 2018; Walling et al., 2015), current measures do not assess 
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patients’ success criteria and priorities for symptom improvement.  To date, only one study has 
examined advanced lung cancer patients’ perceptions of symptom importance (Yount et al., 
2012).  In this study, 50 advanced lung cancer patients ranked their top five most important 
symptoms or concerns, which informed the development of the NCCN-FACT Lung Symptom 
Index-17 (NFLSI-17).  The top-ranked symptoms or concerns were fatigue (n = 22), being able 
to enjoy life (n = 15), and worry that their condition will get worse (n = 15).  Only descriptive 
analyses were conducted, and the final measure did not assess patients’ success criteria or 
priorities for symptom improvement.  To address these gaps in the literature, we developed a 
modified version of the PCOQ focused on eight common symptoms in advanced lung cancer 
patients.  The new PCOQ assesses advanced lung cancer patients’ usual symptom severity level, 
acceptable symptom severity level following symptom treatment, and importance of seeing 
improvement in each symptom.  Thus, the present study had the following specific aims: 
Aim 1: Evaluate the construct validity of the new PCOQ measure for advanced lung cancer 
patients. 
Hypotheses: 
1a. Symptom severity ratings on the PCOQ will be positively correlated with 
standardized assessments of the same symptoms. 
1b. Greater symptom severity on the PCOQ will be correlated with greater medical 
comorbidities and worse functional status and quality of life. 
1c. Greater importance of seeing improvement in each symptom will be correlated with 




2a. Compare the level of symptom severity considered to be acceptable following 
symptom treatment across the eight symptoms. 
2b. Identify subgroups of patients based on the importance of seeing improvement in 
each of the eight symptoms and examine potential correlates of these subgroups, 
including usual symptom severity, demographics, and clinical variables, such as 





CHAPTER 2. METHOD 
This study examined a portion of the data from a Walther-funded study on advanced lung 
cancer patients’ health and well-being.  The Indiana University (IU) Institutional Review Board 
(1901972719) and IU Simon Cancer Center Scientific Review Committee approved study 
procedures.  This study complied with the Health Insurance Portability and Accountability Act 
(HIPAA). 
2.1. Participants 
One hundred and two advanced lung cancer patients were recruited from the IU Simon 
Cancer Center to participate in a one-time survey.  Eligible patients met the following inclusion 
criteria: (1) at least three weeks post-diagnosis of inoperable stage IIIB, IIIC, or IV non-small 
cell lung cancer or inoperable extensive stage small cell lung cancer; (2) received care at the IU 
Simon Cancer Center; (3) at least 18 years old; (4) able to read and speak English; and (5) no 
evidence of severe cognitive impairment.  Cognitive impairment was based on investigator 
judgment or exceeding a clinical cut-point (3 or more errors) on a 6-item validated cognitive 
screening assessment (Callahan, Unverzagt, Hui, Perkins, & Hendrie, 2002). 
2.2. Procedure 
IU Simon Cancer Center medical records were screened to identify potentially eligible 
patients.  Their oncologists were contacted to verify eligibility for the current study.  Eligible 
patients were then mailed an introductory letter signed by their oncologist and the principal 
investigator along with informed consent and HIPAA authorization forms.  The letter included 
the option to opt out of further contact by calling or emailing the research assistant.  
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Approximately one week after the mailing, research assistants called patients who did not opt out 
to discuss the study, administer a cognitive screening assessment (Callahan et al., 2002) to 
interested patients, and obtain verbal informed consent.  Patients who refused to participate were 
asked to provide a reason as well as their age, race/ethnicity, and gender to assess for possible 
selection bias.  Within three days of obtaining consent, patients were sent a REDCap online 
survey via email or a paper survey via postal mail, depending on their preference.  If the 
REDCap or paper survey was not received within approximately two weeks, research assistants 
spoke to the participant up to five times to remind them to complete the survey.  If the REDCap 
survey was not received, automated emails were also sent from REDCap every 4 days for 20 
days following the initial survey invitation to remind them to complete the survey.  Once the 




Participants reported their ethnicity, race, marital status, employment status, and levels of 
education and income.  Age and gender were assessed via medical record review. 
2.3.2. Medical Information 
Advanced stage lung cancer diagnosis date and treatment history (e.g., chemotherapy, 




2.3.3. Medical Comorbidities and Functional Status 
Eight medical conditions diagnosed or treated within the past three years were assessed 
with a self-report measure that has been used in prior research with cancer patients (Kroenke et 
al., 2009).  In a study using a similar measure assessing 10 medical comorbidities, a simple count 
of these comorbidities predicted hospitalization and mortality in older adults (ROC = 0.633 and 
0.659, respectively) (Perkins et al., 2004).  General functional status was assessed with the 
activities and function item from the Patient-Generated Subjective Global Assessment (PG-SGA) 
(Bauer, Capra, & Ferguson, 2002; Dajczman et al., 2008); this is the patient-reported version of 
the Eastern Cooperative Oncology Group (ECOG) Performance Status score (Oken et al., 1982). 
2.3.4. Symptom Treatment History 
Using an author-constructed checklist, participants indicated whether they had received 
treatment in the past three months for each of the eight symptoms assessed by the modified 
PCOQ (i.e., breathlessness, cough, fatigue, sleep problems, pain, nausea, emotional distress, and 
lack of appetite).  Treatment was defined as over-the-counter or prescribed medication, oxygen, 
psychotherapy/counseling, or other treatments. 
2.3.5. Physical and Psychological Symptoms 
Eight physical and psychological symptoms were selected based on their high prevalence 
in advanced lung cancer patients (Alt-Epping et al., 2012; Choi & Ryu, 2018; Walling et al., 
2015).  Four-item NIH Patient-Reported Outcomes Measurement Information System (PROMIS) 
measures (Cella et al., 2010; Pilkonis et al., 2014) assessed anxiety and depressive symptoms on 
a scale from 1 (never) to 5 (always) and fatigue on a scale from 1 (not at all) to 5 (very much).  
In addition, a 4-item PROMIS measure (Yu et al., 2011) assessed sleep disturbance with the first 
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three items rated on a scale ranging from 1 (not at all) to 5 (very much) and the last item (“My 
sleep quality was…”) rated on a scale from 1 (very good) to 5 (very poor).  A 3-item PROMIS 
measure (Cella et al., 2010) also was used to assess pain intensity over the past week on a scale 
from 1 (had no pain) to 5 (very severe) and pain intensity “right now” on a scale from 1 (no 
pain) to 5 (very severe).  Cancer patients provided input during the development of PROMIS 
measures (Garcia et al., 2007), and there is strong evidence of their reliability and validity in 
research with cancer patients (Jensen et al., 2017; Wagner et al., 2015; Yost, Eton, Garcia, & 
Cella, 2011). 
PROMIS measures have not been developed to assess nausea, cough, and lack of 
appetite, and the PROMIS measure of breathlessness only assesses how short of breath patients 
become when performing certain activities (i.e., “dressing yourself without help,” “sweeping or 
mopping”) (Cella et al., 2010).  Therefore, these four symptoms were assessed with items from 
the Memorial Symptom Assessment Scale (MSAS) (Portenoy et al., 1994), a standardized 
assessment developed for cancer patients.  Participants indicated whether they had experienced 
each symptom during the past week.  For each endorsed symptom, patients also indicated how 
often they had experienced the symptom on a scale from 1 (rarely) to 4 (almost constantly), how 
severe the symptom usually was on a scale from 1 (slight) to 4 (very severe), and how much the 
symptom distressed or bothered them on a scale from 0 (not at all) to 4 (very much).  MSAS 
subscales have moderate to high internal consistency (Cronbach’s αs = 0.58 to 0.88) and have 
evidence of construct, convergent, and discriminant validity in research with cancer patients 
(Portenoy et al., 1994). 
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2.3.6. Patient Centered Outcomes Questionnaire 
The Patient Centered Outcomes Questionnaire (M. E. Robinson et al., 2005) was 
modified to include the eight symptoms described above.  The original PCOQ for patients with 
chronic pain consists of five sections measuring usual levels of symptom severity during the past 
week, desired or ideal levels of symptom severity, success criteria for symptom treatment, 
expectations for symptom treatment, and the importance of symptom improvement.  The original 
PCOQ showed adequate test-retest reliability for usual symptom severity over a 48-hour period, 
with values ranging from 0.84 to 0.90, and good concurrent validity with other standardized 
measures of pain, disability, and emotional distress, with r values ranging from 0.52 to 0.75 
(Brown et al., 2008).  Our modified PCOQ measure initially consisted of four sections, with the 
section on desired symptom levels omitted because the ideal outcomes were likely to be “none” 
(Nisenzon et al., 2011).  
To summarize our process of modifying the PCOQ, cognitive interviews were conducted 
via phone with advanced lung cancer patients (N = 10) to obtain in-depth feedback on the 
modified PCOQ measure.  Three coders (Mosher, Krueger, and Secinti) analyzed the transcripts 
using the inductive approach of content analysis (Berg, 2001), with two of the coders generating 
codes independently for each transcript.  The coders met on a regular basis to discuss the codes 
and reach a consensus.  Then the coders generated themes by categorizing recurring codes.  In 
accordance with the generated themes, we made changes to our PCOQ measure.  First, we 
changed the overall formatting of the PCOQ.  The original PCOQ had separate sections for each 
patient-centered outcome (e.g., usual severity level, success criteria).  We found that patients 
referred to each symptom’s usual symptom level when answering the other sections.  Therefore, 
we changed the formatting such that items were organized by symptom rather than patient-
centered outcome.  Second, the original PCOQ required participants to answer each section for 
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every symptom, regardless of whether they experienced the symptom in the past week.  
Participants found it very difficult to respond to items on success criteria, expectations, and 
priorities for symptom improvement for any symptoms that they were not currently 
experiencing.  Therefore, we changed the PCOQ so that when a participant answered 0 (none) 
for the usual severity of a symptom, they would skip the subsequent items for that symptom.  
Third, we omitted the section regarding expectations for symptom treatment, as patients did not 
understand this conceptualization.  For example, many patients could not differentiate between 
“successful” symptom levels and “expected” symptom levels; they expected their treatment to be 
successful and thought that the measure was repetitious. 
Fourth, we found that patients disliked the term “successful” with reference to symptom 
levels following treatment.  When prompted to think out-loud, participants commonly used the 
word “acceptable” as a substitute for the word “successful.”  Thus, we changed the instructions 
for the section regarding success criteria from, “Using the scale below, please indicate the level 
each of these symptoms would have to be at for you to consider symptom treatment successful,” 
to “What level of [symptom] would be acceptable to you if you were to receive treatment for 
[symptom]?”.  Lastly, our initial version of the PCOQ for advanced lung cancer patients included 
ten symptoms: breathlessness, cough, fatigue, sleep problems, neuropathy, pain, nausea, 
emotional distress, lack of appetite, and cognitive problems.  To reduce participant burden, 
neuropathy and cognitive problems were omitted from the final modified PCOQ.  Other reasons 
for omission of these symptoms were neuropathy’s redundancy with pain, the exclusion of 
patients with significant cognitive impairment from the study, and the lack of evidence-based 
treatments in cancer for these symptoms (Asher & Myers, 2015; Bhandari, Mehta, Mavai, & Raj 
Singh, 2016; Finnerup, Sindrup, & Jensen, 2010; Staff, Grisold, Grisold, & Windebank, 2017).  
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The final PCOQ for advanced lung cancer patients focused on eight symptoms with three 
sections.  Because patients in the cognitive interview study asked whether the items referred to 
cancer-related symptoms, the overarching instructions read, “Please rate your usual level of each 
symptom during the past week, whether or not you think it was related to cancer, its treatment, or 
other medical conditions.”  For each symptom, participants reported their usual level of symptom 
severity during the past week on a scale from 0 (none) to 10 (worst imaginable).  If their usual 
symptom severity level was greater than zero, participants then responded to the following 
questions: “What level of [symptom] would be acceptable to you if you were to receive 
treatment for [symptom]?” on a scale from 0 (none) to 10 (worst imaginable) and, “How 
important is it for you to see improvement in your level of [symptom]?” on a scale from 0 (not at 
all important) to 10 (most important). 
2.4. Data Analysis 
 Descriptive statistics, scatterplots, histograms, and residual score analysis were used to 
examine data for normality, linearity, kurtosis, homoscedasticity, and outliers.  I also examined 
the subject to parameter ratio and whether data were missing completely at random using Little’s 
Missing Completely at Random (MCAR) test (Little, 1988).   
 To test Hypotheses 1a-c, construct validity was assessed using correlational analyses in 
SPSS statistical software (version 25.0; SPSS, Chicago, IL, USA).  Construct validity would be 
evidenced by positive correlations between usual symptom severity on the PCOQ and 
assessments of the same symptoms on either PROMIS or MSAS measures (Hypothesis 1a).  
Correlations were also computed between PCOQ usual symptom severity items and indices of 
medical comorbidities, functional status, and quality of life as well as the importance of 
symptom improvement (Hypotheses 1b-c).  We estimated the statistical power to detect a 
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medium to large effect size with the G*Power statistical power analysis program (Faul, 
Erdfelder, Buchner, & Lang, 2009).  A post-hoc power analysis for bivariate correlations was 
performed.  With a sample size of 102 and a two-tailed alpha of 0.01, we have 71-100% power 
to detect medium to large effect sizes (ρs = 0.3-0.6). 
 For secondary objective 2a, linear mixed modeling was performed in SPSS to examine 
differences in levels of acceptable symptom severity following treatment across the eight 
symptoms.  Only participants who reported a usual symptom severity level of one or higher on a 
0 to 10 scale were included in these analyses. 
For secondary objective 2b, a latent profile analysis (LPA) was conducted with Mplus 
statistical software, which uses full information maximum likelihood (FIML) data imputation to 
address missing values (Muthén & Muthén, 2012).  FIML generates implied values for missing 
values based on data patterns (Craig K. Enders, 2001a; Craig K Enders, 2001b).  This strategy 
allows retention of the original sample size and produces more accurate parameter estimates than 
deletion methods and single-imputation methods (Craig K. Enders, 2001a).  The LPA examined 
possible subgroups of advanced lung cancer patients based on importance ratings for each of the 
eight symptoms.  LPA assumes that patterns of the observed variables can be explained by an 
unobserved latent classification variable that divides cases into groups.  This analysis uses 
model-based methods for determining the total number of classes, or subgroups, within the 
sample.  Furthermore, LPA makes probabilistic assignments to classes, whereas hierarchical 
cluster analysis uses absolute methods for class assignment (Hagenaars & McCutcheon, 2002).   
There is no consensus regarding the best criteria for determining the number of classes in 
LPA; however, the Bayesian Information Criterion (BIC) and bootstrap likelihood ratio test 
(BLRT) typically have the best overall performance when determining the number of classes in 
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simulation studies (Nylund, Asparouhov, & Muthén, 2007).  Therefore, a variety of information 
criteria were considered, such as the BIC, BLRT, Akaike Information Criterion (AIC), 
Consistent AIC (CAIC), and sample size adjusted BIC (ssBIC).  For this analysis, the most 
weight was given to the BIC and the BLRT when determining the number of patient subgroups 
based on symptom importance ratings.  Lower values of the BIC and a statistically significant 
value for the BLRT indicate better model fit.  Feasibility of class interpretation was also 
considered when determining model fit (Hagenaars & McCutcheon, 2002).  Entropy measures of 
fit determine the number of classes based on optimal class separation; entropy values closer to 1 
than 0 indicate more class separation (Celeux & Soromenho, 1996; Clark & Muthén, 2009).  
Entropy was used to evaluate whether the classes were well separated in the model. 
LPA is a type of latent class analysis with continuous variables.  Previous research has 
used latent class analysis to identify symptom clusters in cancer patients (Bobevski et al., 2018; 
Doong et al., 2015; Miaskowski et al., 2015; Tometich et al., 2019).  As LPA is exploratory, no 
formal power analysis based on sample size is possible (Dziak, Lanza, & Tan, 2014).  Vermunt’s 
3-step approach using multinomial logistic regressions (Vermunt, 2010) was performed to 
examine potential correlates of patient subgroups, including usual symptom severity, 
demographics, and clinical variables (i.e., cancer stage, time since diagnosis, current cancer 
treatments, symptom treatment history, and medical comorbidities).  A value of p < .01 was 
considered statistically significant due to the number of analyses.  LPA makes probabilistic 
assignments to classes; Vermunt’s 3-step approach accounts for error in class assignment by 
estimating the probability of a patient being assigned to their “true” class or incorrectly assigned 




CHAPTER 3. RESULTS 
Of the 176 patients who were sent recruitment mailings, 115 (65%) completed the 
screening assessment, 21 refused, 9 were deceased, and 27 were lost to follow-up.  Of the 111 
patients who were eligible, all of them consented to participate and 103 (93%) completed the 
survey.  The most common reason for refusal was lack of interest in the study, and other reasons 
included illness or lack of time.  Participants and those who declined participation did not differ 
with respect to gender (ꭓ2(1, N = 132) = .44, p = .51) and age (t(130) = .87, p = .31).  Due to the 
small number of approached patients who were ethnic minorities (n = 21), we were unable to 
conduct the same analysis by race/ethnicity.  One patient was found to be ineligible following 
survey completion.   
Participant characteristics are shown in Tables 1 and 2.  Patients were mostly White 
(82%) and 46% were male, with an average age of 65 years (SD = 11.9).  Patients were, on 
average, 2.6 years (SD = 2.5) from their advanced lung cancer diagnosis.  The majority had 
received chemotherapy (61%) and immunotherapy (55%).   
Descriptive statistics for the PCOQ and standardized symptom measures are found in 
Tables 3 and 4, respectively.  All variables were within the expected ranges for each measure.  
Internal consistency reliability was adequate to good for MSAS subscales (αs = .73 to .82) and 
good to excellent for PROMIS measures (αs = .86 to .96) (see Table 4).  Skewness and kurtosis 
for the main study variables were all less than the absolute values of 3.0 and 8.0, respectively; 
thus, data were within normality guidelines (Kline, 2010).  Little’s MCAR test revealed that data 
were missing completely at random (ꭓ2(1745, N = 102) = 1,839.38, p = 0.06).  Furthermore, less 
than 5% of data were missing for each variable, with the exception of income (9% missing). 
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 For aim #1, correlational analyses were conducted with pairwise deletion.  Consistent 
with hypothesis 1a, the usual severity of all symptoms on the PCOQ was positively correlated 
with standardized assessments of the same symptoms, rs(97 - 102) = 0.69 – 0.91, ps < 0.01 (see 
Table 5).  I also hypothesized positive correlations between PCOQ usual symptom severity and 
medical comorbidities and functional status as well as negative correlations between PCOQ 
usual symptom severity and quality of life (Hypothesis #1b).  Results were partially consistent 
with hypotheses (see Table 6).  The severity of breathlessness, fatigue, sleep problems, and lack 
of appetite was positively correlated with medical comorbidities, rs(101 – 102) = 0.29 – 0.31, ps 
< 0.01, whereas the severity of emotional distress, cough, pain, and nausea showed small, non-
significant correlations with medical comorbidities, rs(99 – 102) =.07 – .20, ps = .04 – .47.  In 
addition, the severity of all symptoms was positively correlated with functional status, rs(98 – 
101) = 0.36 – 0.62, ps < 0.01, and the severity of most symptoms (i.e., breathlessness, fatigue, 
sleep problems, pain, lack of appetite, and emotional distress) was negatively correlated with 
quality of life, rs(97 – 100) = -0.31 – -0.48, ps < 0.01.  The severity of cough and nausea had 
small, non-significant associations with quality of life, rs(98) = -0.25 – -0.26, ps < 0.05.   
Results were also partially consistent with the hypothesis (#1c) that greater symptom 
importance would be correlated with higher levels of symptom severity (see Table 7).  Moderate, 
positive correlations were found between the importance and severity of cough, fatigue, sleep 
problems, and pain, rs(57 – 90) = 0.46 – .58, ps < 0.01.  Whereas importance and severity were 
also moderately correlated for breathlessness, nausea, and emotional distress, results fell short of 
statistical significance, rs(29 – 71) = 0.30 – .39, p < 0.05.  The severity of lack of appetite was 
not significantly correlated with its importance, r(39) = .26, p = .12. 
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For secondary aim #2a, a linear mixed model analysis was conducted to examine 
differences in levels of acceptable symptom severity following symptom treatment across the 
eight symptoms.  Estimated marginal means indicated that the lowest mean acceptable severity 
level was 1.73 for nausea, whereas the highest acceptable level was 2.71 for lack of appetite.  No 
significant differences in acceptable symptom severity were found across the eight symptoms 
(see Table 8).   
For secondary aim #2b, an LPA was conducted to identify subgroups of patients based on 
the importance of seeing improvement in each of the eight symptoms.  Five patients did not 
provide any importance ratings and, thus, were excluded from this analysis.  Five latent profile 
models were estimated (see Table 9).  Due to the BIC’s decreasing value and the statistical 
significance of the BLRT as the model increased from a 3-class to 4-class solution, the 4-class 
model provided the best fit and was the most conceptually meaningful.  However, the 4-class 
model resulted in a subject-to-parameter ratio less than 5:1; therefore, these results are 
interpreted with caution.   
Four patient subgroups were identified (see Figure 2 and Table 10).  Subgroup 1 rated all 
symptoms as low in importance (n=12; 12%).  Subgroup 2 rated bronchial symptoms (i.e., 
breathlessness, cough) and sleep problems as low in importance and all other symptoms as 
moderately important (n=29; 30%).  Subgroup 3 rated nausea and emotional distress as low in 
importance and all other symptoms as moderately important (n=23; 24%).  Subgroup 4 rated all 
symptoms as highly important (n=33; 34%).  Multinomial logistic regressions using Vermunt’s 
3-step approach were conducted to examine differences between subgroups on demographics 
and medical factors, including usual symptom severity, past and current cancer treatments, and 
symptom treatment history (see Tables 11 and 12).  Only one significant difference (p < .01) 
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emerged between subgroups; worse functional status was associated with a greater likelihood of 




CHAPTER 4. DISCUSSION 
The modified PCOQ measure showed evidence of construct validity in advanced lung 
cancer patients.  As hypothesized, the severity of all eight symptoms on the PCOQ was related to 
standardized measures of the same symptoms and functional status.  Additionally, for many 
symptoms on the PCOQ, their severity was correlated with quality of life, medical comorbidities, 
and the importance of seeing improvement in the symptom.  Moderate associations were found 
between the severity of most symptoms and their importance, suggesting that they are related but 
distinct aspects of the symptom experience in advanced lung cancer.  For all symptoms, patients, 
on average, considered a low symptom level to be acceptable following symptom treatment, and 
no differences in acceptable symptom severity were found across the eight symptoms.  Lastly, 
advanced lung cancer patients had heterogeneous priorities for symptom treatment, which were 
largely unrelated to demographic and clinical factors. 
Results partially supported the hypothesis (1b) that functional status, quality of life, and 
medical comorbidities would be correlated with symptom severity.  As hypothesized, increased 
severity of all symptoms on the PCOQ was correlated with worse functional status, consistent 
with prior research with older lung cancer patients (Gift, Jablonski, Stommel, & Given, 2004).  
Furthermore, the severity of most symptoms was negatively correlated with quality of life, as 
found in previous lung cancer research (Lee et al., 2019; Sarna et al., 2004).  However, the 
severity of cough and nausea had small, non-significant associations with quality of life, which 
might be due to the low mean severity of these symptoms.  Consistent with our hypothesis, more 
severe breathlessness, fatigue, sleep problems, and lack of appetite were correlated with greater 
medical comorbidities.  However, the severity of emotional distress, cough, pain, and nausea was 
not correlated with the number of medical comorbidities.  Patients reported, on average, 1.4 
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comorbid medical conditions.  The most frequently endorsed medical condition was 
hypertension, a condition that often has minimal to no symptom burden (Elliott, 2007).  Thus, 
range restriction for medical comorbidities and certain symptoms may have contributed to null 
findings. 
Consistent with hypothesis 1c, the severity of cough, fatigue, sleep problems, and pain 
showed moderate, positive correlations with the importance of seeing improvement in these 
symptoms.  Moderate, positive associations were also found between the severity and importance 
of seeing improvement in breathlessness, nausea, and emotional distress, although they fell short 
of statistical significance.  In addition, the severity and importance of lack of appetite were 
unrelated, which is likely due to low endorsement of this symptom.  Taken together, findings 
suggest that symptom severity and importance are related but distinct constructs.  Other studies 
in chronic pain and cancer also have found significant associations between usual symptom 
severity and patient subgroups based on importance ratings, although the size of these 
associations was not reported (Im Yi et al., 2014; Nisenzon et al., 2011; M. E. Robinson et al., 
2005; Tometich et al., 2018; Zeppieri et al., 2020).  Only two studies have not found significant 
associations between symptom severity and patient subgroups based on importance ratings 
(Rodrigue et al., 2011; Zeppieri et al., 2012).  Their relatively small sample sizes may have 
reduced statistical power for detecting associations. 
During cognitive interviews regarding our modified PCOQ measure, advanced lung 
cancer patients reported several reasons for their symptom importance ratings aside from 
symptom severity.  Some patients connected their lower symptom importance ratings to their 
ability to tolerate higher symptom severity, rather than their actual symptom severity.  One 
patient based her importance ratings on symptoms’ interference with daily activities.  Another 
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patient stated that her low importance ratings reflected a focus on improving survival rather than 
symptoms.  These findings provide possible explanations for the moderate correlations between 
symptom severity and importance that warrant examination in future research. 
Differences in acceptable severity levels were not found across the eight symptoms; for 
all symptoms, low severity was considered acceptable.  The original PCOQ used the term 
“successful” to characterize a positive symptom treatment outcome (M. E. Robinson et al., 
2005).  We changed this term to “acceptable” based on our cognitive interviews with advanced 
lung cancer patients; when prompted to think out-loud, participants commonly used the word 
“acceptable” as a substitute for the word “successful.”  In this study, mean usual severity scores 
for breathlessness, cough, nausea, lack of appetite, and emotional distress were near or below the 
acceptable mean levels for those symptoms, suggesting that patients generally viewed their 
current symptom severity as acceptable.  Fatigue severity was the furthest from its acceptable 
level, consistent with research suggesting that fatigue is the most concerning symptom for 
advanced lung cancer patients (Butt et al., 2008).  The current sample’s acceptable severity 
levels were comparable to metastatic breast cancer patients’ and chronic pain patients’ success 
criteria for symptom improvement (O'Brien et al., 2010; M. E. Robinson et al., 2005; Tometich 
et al., 2018; Zeppieri et al., 2012).  Patients with chronic pain often adjust their success criteria 
such that higher symptom levels are more acceptable after experiencing partial pain relief with 
treatment (Brown et al., 2008).  Therefore, our current sample’s generally low acceptable 
symptom levels may be related to their low rates of recent symptom treatment.  Although about 
one third of our sample had received treatment for pain in the past three months, only small 
subgroups received treatment for other symptoms (range = 9-28%).   
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Four distinct patient subgroups were identified based on priorities for symptom 
improvement.  Subgroup 1 rated all symptoms as low in importance.  Subgroup 2 rated bronchial 
symptoms (i.e., breathlessness, cough) and sleep problems as low in importance and all other 
symptoms as moderately important.  Subgroup 3 rated nausea and emotional distress as low in 
importance and all other symptoms as moderately important, and subgroup 4 rated all symptoms 
as highly important.  These results suggest that advanced lung cancer patients have 
heterogeneous priorities for symptom improvement.  Previous work in chronic pain has found 
similar heterogeneity.  Specifically, studies have typically found two or three subgroups of 
patients based on importance ratings for pain, fatigue, distress, and interference with daily 
activities, with one patient subgroup rating all symptoms as highly important (Im Yi et al., 2014; 
Nisenzon et al., 2011; M. E. Robinson et al., 2005; Zeppieri et al., 2012).  In addition, a pain-
focused importance subgroup was found in nearly all studies of patients with chronic pain (Im Yi 
et al., 2014; M. E. Robinson et al., 2005; Zeppieri et al., 2012).  Conversely, only one study in 
chronic pain has found a subgroup rating all symptoms as low in importance (Nisenzon et al., 
2011).  The low importance subgroup in our study may be related to low usual symptom severity 
(i.e., mean rating <3 on a 0 to 10 scale), except for fatigue.  Nearly a third of patients in our 
sample were on a cancer treatment break; without treatment side effects, patients may have not 
experienced symptoms that were distressing and important to improve at the time of this study. 
Only one prior study has modified the PCOQ to examine subgroups of cancer patients 
based on symptom importance ratings (Tometich et al., 2018).  In this study, advanced breast 
cancer patients rated the importance of 10 common symptoms and the following patient 
subgroups were found: (1) those who rated thinking problems, sleep problems, and fatigue as 
highly important, (2) those who rated pain as moderately important, and (3) those who rated all 
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symptoms as highly important.  Differences in sample characteristics (e.g., gender, time since 
diagnosis, disease and treatment side effects) between this study and the current project likely 
contributed to differences in patient subgroups based on symptom importance.  In addition, the 
number and type of the symptoms included in the PCOQ differed between the two projects, and 
the metastatic breast cancer patients rated the importance of symptoms regardless of their current 
symptom level.  Nevertheless, both studies found a subgroup that rated all symptoms as highly 
important.  As advanced cancer patients, on average, experience 11 symptoms of varying 
severity (Declan Walsh & Rybicki, 2006), prioritizing treatment of certain symptoms may be 
challenging for some patients.  The lack of a pain-focused subgroup in the current sample may 
be related to the even more expansive and severe symptom burden in advanced lung cancer 
compared to advanced breast cancer (Cleeland et al., 2013; Cooley, 2000). 
Demographics and medical factors, such as usual symptom severity, cancer treatments, 
and symptom treatment history, were examined as correlates of subgroups based on symptom 
importance.  Only one factor was associated with subgroups; worse functional status was related 
to a higher likelihood of being in subgroup 3 (rating all symptoms as moderately important 
except for low nausea and emotional distress) than subgroup 1 (rating all symptoms as low in 
importance).  Associations between functional status and patient subgroups based on symptom 
importance have rarely been examined, with the study in metastatic breast cancer finding no 
relationship between these variables (Tometich et al., 2018).  Our largely null findings may be a 
function of the small sample size and relatively homogeneous sample with respect to certain 
characteristics (e.g., race/ethnicity, symptom treatment history).  Additionally, our results mirror 
findings in the general PCOQ literature; few demographic and clinical correlates of subgroups 
based on symptom importance have been found (Im Yi et al., 2014; Nisenzon et al., 2011; M. E. 
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Robinson et al., 2005; Rodrigue et al., 2011; Tometich et al., 2018; Zeppieri et al., 2020; 
Zeppieri et al., 2012).  However, several studies in cancer and chronic pain have found that age, 
education, and usual symptom severity are correlated with these subgroups (Im Yi et al., 2014; 
Nisenzon et al., 2011; M. E. Robinson et al., 2005; Tometich et al., 2018; Zeppieri et al., 2020).    
In this study, symptom treatment history was unrelated to patient subgroups based on 
symptom importance.  Some patients had received treatment for symptoms and perceived them 
to be at an acceptable level; thus, these symptoms might be viewed as no longer important to 
treat.  Conversely, other patients might have recently begun treatment for symptoms and may 
have rated them as highly important to improve.  In addition, because experiences with symptom 
treatment are not uniformly successful, the relationship between symptom treatment history and 
symptom importance is likely to be complex. 
Limitations of this study should be noted.  It is possible that patients who agreed to 
participate in our survey differed than those who chose not to participant.  Study participants 
may have had fewer or less severe symptoms than non-participants, as a common reason for 
refusal was not feeling well enough to participate.  Additionally, except for the medical record 
data, all measures were self-reported.  Inaccurate retrospective symptom recalls and social 
desirability biases may have affected symptom reports.  However, many of the symptoms are 
subjective experiences that cannot be evaluated objectively.  There are also limitations regarding 
the generalizability of these findings.  We enrolled patients with advanced lung cancer at one 
academic medical center in the midwestern United States, most of whom were Caucasian.  Thus, 
our findings may not generalize to patients with other cancer types, ethnic minorities, or those in 
other geographic settings.  Additionally, the relatively small sample size and insufficient 
variance in certain variables contributed to null findings.  Lastly, the cross-sectional design did 
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not allow for examination of test-retest reliability in our study and change in acceptable symptom 
severity and symptom treatment priorities over time.  These factors are likely to vary throughout 
the cancer experience.  Due to these limitations, the results of this study provide only preliminary 
evidence of our PCOQ’s psychometric properties. 
These findings have important implications for the tailoring of symptom treatment for 
advanced lung cancer patients.  In general, results point to the importance of considering patient 
preferences, such as their acceptable symptom severity and symptom improvement priorities, 
when discussing symptom treatment options to foster shared decision-making.  Specifically, 
results suggest that advanced lung cancer patients typically require low symptom severity levels 
to consider symptoms acceptable, highlighting the need for patient-provider discussions about 
possible symptom treatment outcomes.  Results also suggest that advanced lung cancer patients 
have heterogeneous priorities for symptom improvement.  Thus, providers can ask patients about 
their individual priorities and goals for symptom treatment to better inform shared decision-
making and patient-centered care.  For example, after assessing the severity of patient symptoms, 
a provider could ask, “What is the most important symptom to treat?” 
Furthermore, our findings indicate that fatigue may be an important symptom for 
intervention in advanced lung cancer patients, as it had the highest mean severity rating and was 
also rated as highly important.  Previous research with advanced lung cancer patients has found 
that fatigue often co-occurs with other symptoms (Choi & Ryu, 2018; Henoch et al., 2009); 
therefore, treating other symptoms may help reduce fatigue.  For example, evidence suggests that 
cognitive-behavioral interventions may help improve the severity of the pain-fatigue-sleep 
symptom cluster in patients with various cancers (Kwekkeboom, Cherwin, Lee, & Wanta, 2010).  
However, treatment for one symptom, such as steroids or stimulants for fatigue, may negatively 
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impact other symptoms, such as anxiety and sleep problems (Escalante & Manzullo, 2009; 
Sturdza et al., 2008).  Thus, providers should discuss symptom treatment side effects with 
advanced lung cancer patients to ensure that treatment is consistent with their priorities for 
symptom improvement. 
Further research is needed to examine the psychometric properties of our measure in 
larger, more diverse samples that fully represent the advanced lung cancer population.  
Additionally, longitudinal research should be conducted to provide evidence of test-retest 
reliability.  Future research could also validate the PCOQ in other advanced cancer populations, 
such as prostate or gastrointestinal cancer patients.  Although the PCOQ would require 
modification to reflect the symptom experiences of each cancer group, a number of symptoms 
are prevalent across advanced cancers (Teunissen et al., 2007; D. Walsh, Donnelly, & Rybicki, 
2000).  Thus, researchers could use the PCOQ to determine whether acceptable severity levels or 
treatment priorities for certain symptoms vary across advanced cancer diagnoses.   
Future research may also examine how acceptable symptom levels and symptom 
improvement priorities change over the entire lung cancer trajectory from diagnosis to phases of 
treatment and end-of-life care.  These perceptions are expected to change as symptom severity 
fluctuates.  For example, chemotherapy and radiation are related to increased fatigue (Bower, 
2014), and symptom burden generally increases over time in advanced lung cancer (LeBlanc et 
al., 2015; Lövgren, Tishelman, Sprangers, Koyi, & Hamberg, 2008).  Additionally, stepped-care 
intervention trials targeting symptom clusters could consider patients’ priorities for symptom 
improvement when determining the sequence of care.  This research could ultimately inform 
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Table 1  
Participant Demographic Characteristics (N = 102) 
Characteristic  
Age  
   Mean (SD) 64.96 (11.87) 
   Range 34 – 92 
Gender, no. (%)  
   Male 47 (46.08) 
   Female 55 (53.92) 
Race, no. (%)  
   White 84 (82.35) 
   African American/Black 13 (12.75) 
   Othera 5 (4.90) 
Ethnicity, no. (%)  
   Non-Hispanic 96 (98.97) 
   Hispanic 1 (0.98) 
Married or Living with a Partner, no. (%) 68 (66.67) 
Employed, no. (%) 27 (26.47) 
Level of Education, no. (%)  
   No college 34 (33.33) 
   Some college 32 (31.37) 
   Graduated college/graduate school 36 (35.29) 
Household Income, no. (%)  
   $0 - $30,999 21 (20.59) 
   $31,000 - $99,999 48 (47.06) 
   $100,000 or more 24 (23.53) 




Table 2  
Participant Medical Characteristics (N = 102) 
Medical Characteristic  
Lung Cancer Stage, no. (%)  
   NSCLC IIIB 16 (15.69) 
   NSCLC IIIC           1 (0.98) 
   NSCLC IV  78 (76.47) 
   SCLC Extensive  7 (6.86) 
Years since Advanced or Extensive Stage Diagnosis  
   Mean (SD) 2.60 (2.54) 
   Range 0.06 – 11.30 
Cancer Treatment History,a no. (%)  
   Surgery 31 (30.39) 
   Chemotherapy 62 (60.78) 
   Radiation 36 (35.29) 
   Chemoradiation 26 (25.49) 
   Targeted Therapy 39 (38.24) 
   Immunotherapy 56 (54.90) 
   Clinical Trial 14 (13.73) 
Current Cancer Treatment,b no. (%)  
   Chemotherapy 17 (16.67) 
   Radiation           1 (0.98) 
   Chemoradiation 3 (2.94) 
   Targeted Therapy 27 (26.47) 
   Immunotherapy 32 (31.37) 
   Clinical Trial           0 (0.00) 
Symptom Treatment History,c no. (%)  
   Breathlessness 28 (27.45) 
   Cough 21 (20.59) 
   Fatigue 22 (21.57) 
   Sleep Problems 24 (23.53) 
   Pain 36 (35.29) 
   Nausea 23 (22.55) 
   Lack of Appetite 9 (8.82) 
   Emotional Distress 17 (16.67) 
Medical Comorbidities  
   Mean (SD) 1.44 (1.04) 
   Range 0 – 4 
Medical Comorbidities, no. (%)  
   Asthma, emphysema, or chronic bronchitis 28 (27.45) 
   Hypertension 55 (53.92) 
   Diabetes 15 (14.71) 
   Arthritis  25 (24.51) 
   Angina, heart failure, or other types of heart disease         10 (9.80) 
   Strokes, seizures, Parkinson’s disease, or other neurological condition 5 (4.90) 
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   Liver disease 3 (2.94) 
   Kidney or renal disease 6 (5.88) 
Note. NSCLC = non-small cell lung cancer.  SCLC = small cell lung cancer.   
aTreatment >4 weeks before study completion.  
bTreatment <4 weeks before study completion.  




Table 3  
Descriptive Statistics and Normality Estimates for PCOQ Constructs 
     Normality estimate 
Variable n Mean SD Range Skewness Kurtosis 
Usual Severity       
Breathlessness 102 2.26 2.20 0 – 10   .93 .60 
Cough 100 1.87 2.25 0 – 9 1.18 .48 
Fatigue 101 4.39 2.72 0 – 10 .04 -.92 
Sleep problems 102 3.09 2.78 0 – 9 .49 -.95 
Pain 99 3.04 2.80 0 – 9 .32 -1.33 
Nausea 100 1.00 1.96 0 – 8 2.12 3.74 
Lack of appetite 102 1.79 2.74 0 – 10 1.44 1.04 
Emotional distress 102 2.22 2.64 0 – 10 1.14 .57 
Acceptable Severity       
Breathlessness 70 2.31 2.18 0 – 8 .82 -.24 
Cough 58 2.09 1.92 0 – 8 1.09 .77 
Fatigue 88 2.60 1.88 0 – 9 .59 .30 
Sleep problems 73 2.70 2.31 0 – 10 1.33 1.76 
Pain 66 2.71 2.13 0 – 10 1.02 1.11 
Nausea 29 2.14 2.28 0 – 10 1.53 3.56 
Lack of appetite 40 3.10 2.18 0 – 9 .61 .13 
Emotional distress 58 2.41 1.70 0 – 8 .81 1.33 
Importance       
Breathlessness 71 6.42 3.13 0 – 10 -.52 -.81 
Cough 57 5.47 3.46 0 – 10 -.05 -1.51 
Fatigue 90 6.54 2.94 0 – 10 -.70 -.48 
Sleep problems 72 5.76 3.09 0 – 10 -.14 -1.09 
Pain 66 6.85 2.93 0 – 10 -.64 -.53 
Nausea 29 5.55 3.38 0 – 10 -.01 -1.18 
Lack of appetite 39 5.18 3.03 0 – 10 -.04 -.89 
Emotional distress 58 6.09 3.24 0 – 10 -.28 -1.27 







Table 4  
Descriptive Statistics and Normality Estimates for PROMIS and MSAS Symptom Severity  
     Normality estimate  
Variable n Mean SD Range Skewness Kurtosis Cronbach’s α 
Breathlessnessa 100 1.32 1.19 0.00 – 4.00 0.12 -1.35 .82 
Cougha  100 0.95 1.09 0.00 – 3.73 0.60 -1.02 .79 
Fatigueb  102 11.74 4.33 4.00 – 20.00 0.22 -0.86 .96 
Sleep problemsb  102 10.49 3.92 4.00 – 20.00 0.32 -0.48 .86 
Painb  102 6.53 3.00 3.00 – 13.00 0.25 -1.11 .91 
Nauseaa  102 0.45 0.97 0.00 – 3.67 1.94 2.43 .81 
Lack of appetitea 100 0.73 1.17 0.00 – 4.00 1.19 -0.13 .73 
Anxietyb  101 7.57 3.37 4.00 – 17.00 0.80 -0.23 .88 
Depressionb  101 6.94 3.26 4.00 – 16.00 0.99 -0.03 .88 







Table 5  
Correlations Between PCOQ Symptom Severity and Standardized Assessments of the Same Symptoms (ns = 97 – 102) 
 Breathlessnessa Cougha Fatigueb 
Sleep 
problemsb Painb Nauseaa 
Lack of 
appetitea Anxietyb Depressionb 
1. PCOQ 
Breathlessness 
0.72* 0.24 0.45* 0.17 0.36* 0.16 0.21 0.31* 0.27* 
2. PCOQ Cough 0.39* 0.87* 0.34* 0.27* 0.19 0.22 0.34* 0.26* 0.20 
3. PCOQ Fatigue 0.50* 0.25 0.81* 0.37* 0.48* 0.36* 0.35* 0.46* 0.50* 
4. PCOQ Sleep 
problems 
0.25 0.18 0.43* 0.76* 0.33* 0.01 0.26* 0.33* 0.30* 
5. PCOQ Pain 0.39* 0.07 0.52* 0.33* 0.84* 0.14 0.15 0.29* 0.24 
6. PCOQ Nausea 0.17 0.13 0.34* 0.03 0.25 0.91* 0.46* 0.30* 0.30* 
7. PCOQ Lack of 
appetite 




0.21 0.07 0.41* 0.20 0.24 0.13 0.11 0.69* 0.69* 
Note.  Pairwise correlations.  PCOQ = Patient Centered Outcomes Questionnaire.   
aMSAS (Memorial Symptom Assessment Scale).  bPROMIS (Patient Reported Outcomes Measurement Information System).   






Table 6  
Correlations Between Usual Symptom Severity on the PCOQ and Functional Status, Medical Comorbidities, 
and Quality of Life (ns = 97 – 102) 
 
Medical                      
Comorbidities 
          Functional    
Status          Quality of Life 
1. Breathlessness  .31* .54* -.34* 
2. Cough  .16 .36* -.25 
3. Fatigue .29* .62* -.44* 
4. Sleep problems  .29* .40* -.31* 
5. Pain  .15 .45* -.39* 
6. Nausea  .07 .50* -.26 
7. Lack of appetite  .29* .56* -.38* 
8. Emotional distress  .20 .41* -.48* 
Note.  Pairwise correlations.  PCOQ = Patient Centered Outcomes Questionnaire. 






Table 7  



























.30 .22 .28* .28 .24 .29 .01 .09 
2. Cough severity .15 .58* .12 .13 -.04 .10 .08 -.01 
3. Fatigue severity .11 .11 .46* .28 .27 .46 .18 .13 
4. Sleep problems 
severity 
.00 .24 .20 .57* .39* .16 .02 .17 
5. Pain severity .17 .07 .21 .18 .49* .36 .05 .24 
6. Nausea severity -.08 .14 .10 -.02 .11 .39 .23 .19 
7. Lack of appetite 
severity 
-.23 .16 .06 .07 .18 .50* .26 .01 
8. Emotional 
distress severity 
.01 -.10 .20 .06 .17 .12 .22 .30 
Note.  Pairwise correlations.  PCOQ = Patient Centered Outcomes Questionnaire. 
*Correlation is significant at the 0.01 level (two-tailed).   
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Table 8  







Severity SE   df    p-value 
Symptoms      
Breathlessness 2.28  .24 299.45  
Cough 2.01  .25 343.30  
Fatigue 2.62  .22 248.75  
Sleep problems 2.48  .23 290.02  
Pain 2.52  .24 313.06  
Nausea 1.73  .33 464.23  
Lack of appetite 2.71  .29 421.00  







Lack of appetite 
Emotional distress 
  .27 .27 391.43 1.00 
-.35 .24 392.69 1.00 
-.21 .26 396.60 1.00 
-.24 .26 392.51 1.00 
 .55 .34 395.64 1.00 
-.43 .31 395.40 1.00 







Lack of appetite 
Emotional distress 
-.27 .27 391.43 1.00 
-.61 .26 395.04 .54 
-.47 .27 400.31 1.00 
-.51 .28 394.43 1.00 
 .29 .35 397.16 1.00 
-.70 .32 396.48 .82 







Lack of appetite 
Emotional distress 
.35 .24 392.69 1.00 
.61 .26 395.04 .54 
.14 .24 395.40 1.00 
.10 .25 396.04 1.00 
.90 .33 398.34 .21 
-.09 .30 398.02 1.00 










Lack of appetite 
Emotional distress 
 .21 .26 396.60 1.00 
 .47 .27 400.31 1.00 
-.14 .24 395.40 1.00 
-.04 .26 392.24 1.00 
 .76 .34 400.46 .80 
-.23 .31 399.00 1.00 







Lack of appetite 
Emotional distress 
 .24 .26 392.51 1.00 
 .51 .28 394.43 1.00 
-.10 .25 396.04 1.00 
 .04 .26 392.24 1.00 
 .79 .35 397.53 .64 
-.19 .31 398.19 1.00 







Lack of appetite 
Emotional distress 
-.55 .34 395.64 1.00 
-.29 .35 397.16 1.00 
-.90 .33 398.34 .21 
-.76 .34 400.46 .80 
-.79 .35 397.53 .64 
-.98 .37 388.79 .24 
-.64 .35 396.75 1.00 








.43 .31 395.40 1.00 
.70 .32 396.48 .82 
.09 .30 398.02 1.00 
.23 .31 399.00 1.00 
.19 .31 398.19 1.00 
.98 .37 388.79 .24 








Lack of appetite 
 .09 .27 392.72 1.00 
 .35 .29 396.24 1.00 
-.26 .26 395.90 1.00 
-.12 .27 395.99 1.00 
-.15 .28 396.17 1.00 
 .64 .35 396.75 1.00 
-.34 .32 393.21 1.00 
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Table 9  
Measures of Model Fit for Latent Profile Analysis 
Classes LL  BIC  AIC CAIC ssBIC   E   BLRT 
1 -1280.99  2607.72  2581.97 2617.72 2576.14  N/A  N/A 
2 -1133.18  2380.72  2316.36 2405.72 2301.78  0.88  p < .01 
3 -1106.20  2367.93  2280.39 2401.93 2260.57  0.80  p < .01 
4 -1080.99  2358.69  2247.97 2401.68 2222.91  0.83  p < .01 
5 -1063.77  2365.43  2231.55 2417.43 2201.23  0.85  p = .03 
6 -1044.72  2368.50  2211.44 2429.50 2175.89   0.88   p = .01 
Note.  LL = Log Likelihood.  BIC = Bayesian Information Criterion.  AIC = Akaike Information 
Criterion.  CAIC = Consistent Akaike Information Criterion.  ssBIC = Sample Sized Adjusted 







Table 10  
Descriptive Statistics for Classes Based on Symptom Importance 




Means (SE) Range  
Estimated 
Marginal 
Means (SE) Range  
Estimated 
Marginal 
Means (SE) Range  
Estimated 
Marginal 
Means (SE) Range 
Symptom Importance            
Breathlessness 2.70 (0.72) 0-5  3.94 (0.50) 0-7  6.74 (0.51) 2-10  9.27 (0.39) 5-10 
Cough 1.39 (0.57) 0-4  2.30 (0.35) 0-5  6.92 (0.48) 3-10  9.23 (0.37) 8-10 
Fatigue 1.73 (0.69) 0-5  6.73 (0.45) 1-10  6.60 (0.50) 4-9  8.31 (0.41) 1-10 
Sleep problems 2.49 (0.77) 0-5  3.78 (0.50) 0-9  6.14 (0.56) 3-10  8.39 (0.49) 3-10 
Pain 1.92 (0.74) 0-6  6.34 (0.46) 3-10  5.54 (0.49) 1-9  9.52 (0.37) 8-10 
Nausea 1.51 (0.89) 0-4  4.48 (0.58) 1-8  3.76 (0.67) 0-5  9.25 (0.59) 5-10 
Lack of appetite 0.97 (1.35) 0-1  4.44 (0.66) 0-7  4.54 (0.67) 1-9  7.91 (0.69) 0-10 
Emotional distress 1.29 (0.69) 0-2  5.90 (0.43) 3-9  3.16 (0.41) 0-6  9.47 (0.31) 8-10 
 
Means 
(SD) Range  
Means 
(SD) Range  
Means 
(SD) Range  
Means 
(SD) Range 
Differing Variable            
Functional status 0.58 (0.67) 0-2   1.17 (0.76) 0-3   1.48 (0.90) 0-3   1.25 (0.92) 0-3 
Note.  Class 1 = Low Importance, n = 12.  Class 2 = Moderate Importance except for low bronchial symptoms and sleep 
importance, n = 29.  Class 3 = Moderate Importance except for low nausea and emotional distress importance, n = 23.  Class 4 = 







Table 11  
Multinomial Logistic Regression Results using Class 4 as a Reference 
  Class 1 v 4 Class 2 v 4 Class 3 v 4 
  B (SE) OR (95% CI) B (SE) OR (95% CI) B (SE) OR (95% CI) 
Age .00 (.03) 1.00 (.95, 1.07) .00 (.03) 1.00 (.96, 1.05) .00 (.03) 1.00 (.95, 1.06) 
       
Gender (Male) -.77 (.74) .46 (.11, 1.96) -.65 (.61) .52 (.16, 1.72) -1.12 (.68) .33 (.09, 1.23) 
       
Married/Living with 
Partner 
.53 (.75) 1.71 (.40, 7.35) 1.12 (.67) 3.05 (.82, 11.36) .47 (.67) 1.61 (.44, 5.91) 
       
Employed -.30 (.81) .74 (.15, 3.63) -.31 (.65) .74 (.20, 2.65) -.88 (.84) .42 (.08, 2.16) 
       
Educationa       
Some College .61 (.99) 1.84 (.27, 12.71) 1.29 (.77) 3.64 (.81, 16.44) 1.34 (.86) 3.82 (.72, 20.42) 
Graduated College 1.48 (.88) 4.40 (.78, 24.77) 1.51 (.78) 4.51 (.98, 20.75) 1.46 (.87) 4.30 (.78, 23.81) 
       
Incomeb       
$31,000 - $99,000 1.94 (1.28) 6.99 (.57, 85.17) .38 (.82) 1.47 (.30, 7.26) 1.78 (.96) 5.92 (.90, 39.03) 
$100,000 or more 2.17 (1.36) 8.77 (.61, 126.17) .12 (1.11) 1.13 (.13, 9.99) 1.87 (1.06) 6.50 (.81, 52.24) 
       
Time Since Diagnosis .19 (.15) 1.20 (.89, 1.62) .16 (.14) 1.17 (.90, 1.52) .20 (.14) 1.22 (.92, 1.61) 
       
Functional Status -1.25 (.58) .29 (.09, .89) -.12 (.36) .89 (.44, 1.81) .41 (.40) 1.51 (.69, 3.28) 
       
Number of Medical 
Comorbidities 
-.27 (.35) .76 (.38, 1.52) -.22 (.28) .80 (.46, 1.39) -.22 (.32) .80 (.43, 1.49) 
       






       
Cancer Treatment 
Historyc 
      
Surgery -.42 (.81) .66 (.14, 3.20) -.77 (.71) .46 (.12, 1.86) -.12 (.69) .89 (.23, 3.43) 
Chemotherapy -.82 (.74) .44 (.10, 1.86) .48 (.64) 1.62 (.47, 5.65) .01 (.66) 1.01 (.28, 3.68) 
Radiation -1.34 (.93) .26 (.04, 1.60) -1.04 (.70) .35 (.09, 1.40) .55 (.66) 1.74 (.48, 6.31) 
Chemoradiation -.28 (.81) .76 (.16, 3.72) -.59 (.70) .55 (.14, 2.19) -.22 (.72) .81 (.20, 3.29) 
Targeted Therapy 1.45 (.79) 4.25 (.91, 19.96) 1.38 (.68) 3.98 (1.06, 14.98) 1.42 (.73) 4.12 (.98, 17.36) 
Immunotherapy -.31 (.72) .74 (.18, 3.02) -.45 (.59) .64 (.20, 2.04) .20 (.67) 1.22 (.33, 4.52) 
Clinical Trial .11 (.97) 1.12 (.17, 7.44) -.12 (.84) .88 (.17, 4.55) -.21 (.95) .81 (.13, 5.19) 
       
Current Cancer 
Treatmentd 
      
Chemotherapy .95 (.92) 2.57 (.43, 15.46) .43 (.85) 1.54 (.29, 8.15) .47 (.92) 1.60 (.27, 9.69) 
Targeted Therapy 1.06 (.99) 2.87 (.42, 19.92) 1.54 (.84) 4.67 (.90, 24.09) 1.84 (.88) 6.30 (1.12, 35.56) 
Immunotherapy -1.13 (.94) .32 (.05, 2.04) -.23 (.62) .80 (.24, 2.68) -.29 (.69) .75 (.19, 2.90) 
       
Usual Severity       
Breathlessness -.27 (.18) .76 (.54, 1.08) -.33 (.15) .72 (.54, .97) -.25 (.16) .78 (.58, 1.06) 
Cough -.22 (.19) .80 (.55, 1.16) -.28 (.16) .76 (.55, 1.03) .10 (.13) 1.11 (.85, 1.44) 
Fatigue -.41 (.17) .67 (.48, .94) -.10 (.12) .90 (.72, 1.14) -.11 (.13) .89 (.69, 1.16) 
Sleep Problems -.33 (.16) .72 (.53, .98) -.20 (.11) .82 (.66, 1.02) -.12 (.12) .89 (.71, 1.12) 
Pain -.41 (.19) .66 (.45, .97) -.13 (.11) .88 (.71, 1.09) -.11 (.12) .89 (.71, 1.13) 
Nausea -.27 (.26) .77 (.46, 1.26) .02 (.13) 1.02 (.80, 1.32) -.19 (.21) .83 (.54, 1.26) 
Lack of Appetite -.24 (.22) .79 (.51, 1.22) .07 (.11) 1.07 (.87, 1.32) .07 (.12) 1.07 (.85, 1.35) 
Emotional Distress -.55 (.30) .58 (.32, 1.03) .05 (.10) 1.05 (.86, 1.29)  -.19 (.14) .83 (.63, 1.09) 
       
Symptom Treatment 
Historye 
      






Fatigue -.81 (1.46) .45 (.03, 7.77) 1.27 (.73) 3.57 (.85, 14.98) .78 (.83) 2.19 (.43, 11.14) 
Sleep Problems -.53 (.96) .59 (.09, 3.90) .43 (.65) 1.54 (.43, 5.47) -.19 (.79) .83 (.18, 3.88) 
Pain .23 (.73) 1.26 (.30, 5.29) .08 (.61) 1.08 (.33, 3.55) -.10 (.68) .91 (.24, 3.45) 
Lack of Appetite -.47 (1.25) .62 (.05, 7.25) -.13 (.89) .88 (.15, 4.99) -1.46 (1.76) .23 (.01, 7.26) 
Note.  The following variables were removed from analyses due to insufficient variance: current cancer treatment of radiation, 
chemoradiation, and clinical trial; symptom treatment history of cough, nausea, and emotional distress; and race/ethnicity.  OR = Odds 
Ratio.  CI = Confidence Interval.  PCOQ = Patient Centered Outcomes Questionnaire.  Class 1 = Low Importance, n = 12.  Class 2 = 
Moderate Importance except for low bronchial symptoms and sleep importance, n = 29.  Class 3 = Moderate Importance except for low 
nausea and emotional distress importance, n = 23.  Class 4 = High Importance, n = 33. 
aNo college education used as the reference group. 
bHousehold income less than $31,000 used as the reference group. 
cTreatment >4 weeks before study completion.   
dTreatment <4 weeks before study completion.   







Table 12  
Multinomial Logistic Regression Results using Class 4 as a Reference 
  Class 1 v 4 Class 2 v 4 Class 3 v 4 
  B (SE) OR (95% CI) B (SE) OR (95% CI) B (SE) OR (95% CI) 
Age .00 (.03) 1.00 (.95, 1.07) .00 (.03) 1.00 (.96, 1.05) .00 (.03) 1.00 (.95, 1.06) 
       
Gender (Male) -.77 (.74) .46 (.11, 1.96) -.65 (.61) .52 (.16, 1.72) -1.12 (.68) .33 (.09, 1.23) 
       
Married/Living with 
Partner 
.53 (.75) 1.71 (.40, 7.35) 1.12 (.67) 3.05 (.82, 11.36) .47 (.67) 1.61 (.44, 5.91) 
       
Employed -.30 (.81) .74 (.15, 3.63) -.31 (.65) .74 (.20, 2.65) -.88 (.84) .42 (.08, 2.16) 
       
Educationa       
Some College .61 (.99) 1.84 (.27, 12.71) 1.29 (.77) 3.64 (.81, 16.44) 1.34 (.86) 3.82 (.72, 20.42) 
Graduated College 1.48 (.88) 4.40 (.78, 24.77) 1.51 (.78) 4.51 (.98, 20.75) 1.46 (.87) 4.30 (.78, 23.81) 
       
Incomeb       
$31,000 - $99,000 1.94 (1.28) 6.99 (.57, 85.17) .38 (.82) 1.47 (.30, 7.26) 1.78 (.96) 5.92 (.90, 39.03) 
$100,000 or more 2.17 (1.36) 8.77 (.61, 126.17) .12 (1.11) 1.13 (.13, 9.99) 1.87 (1.06) 6.50 (.81, 52.24) 
       
Time Since Diagnosis .19 (.15) 1.20 (.89, 1.62) .16 (.14) 1.17 (.90, 1.52) .20 (.14) 1.22 (.92, 1.61) 
       
Functional Status -1.25 (.58) .29 (.09, .89) -.12 (.36) .89 (.44, 1.81) .41 (.40) 1.51 (.69, 3.28) 
       
Number of Medical 
Comorbidities 
-.27 (.35) .76 (.38, 1.52) -.22 (.28) .80 (.46, 1.39) -.22 (.32) .80 (.43, 1.49) 
       






       
Cancer Treatment 
Historyc 
      
Surgery -.42 (.81) .66 (.14, 3.20) -.77 (.71) .46 (.12, 1.86) -.12 (.69) .89 (.23, 3.43) 
Chemotherapy -.82 (.74) .44 (.10, 1.86) .48 (.64) 1.62 (.47, 5.65) .01 (.66) 1.01 (.28, 3.68) 
Radiation -1.34 (.93) .26 (.04, 1.60) -1.04 (.70) .35 (.09, 1.40) .55 (.66) 1.74 (.48, 6.31) 
Chemoradiation -.28 (.81) .76 (.16, 3.72) -.59 (.70) .55 (.14, 2.19) -.22 (.72) .81 (.20, 3.29) 
Targeted Therapy 1.45 (.79) 4.25 (.91, 19.96) 1.38 (.68) 3.98 (1.06, 14.98) 1.42 (.73) 4.12 (.98, 17.36) 
Immunotherapy -.31 (.72) .74 (.18, 3.02) -.45 (.59) .64 (.20, 2.04) .20 (.67) 1.22 (.33, 4.52) 
Clinical Trial .11 (.97) 1.12 (.17, 7.44) -.12 (.84) .88 (.17, 4.55) -.21 (.95) .81 (.13, 5.19) 
       
Current Cancer 
Treatmentd 
      
Chemotherapy .95 (.92) 2.57 (.43, 15.46) .43 (.85) 1.54 (.29, 8.15) .47 (.92) 1.60 (.27, 9.69) 
Targeted Therapy 1.06 (.99) 2.87 (.42, 19.92) 1.54 (.84) 4.67 (.90, 24.09) 1.84 (.88) 6.30 (1.12, 35.56) 
Immunotherapy -1.13 (.94) .32 (.05, 2.04) -.23 (.62) .80 (.24, 2.68) -.29 (.69) .75 (.19, 2.90) 
       
Usual Severity       
Breathlessness -.27 (.18) .76 (.54, 1.08) -.33 (.15) .72 (.54, .97) -.25 (.16) .78 (.58, 1.06) 
Cough -.22 (.19) .80 (.55, 1.16) -.28 (.16) .76 (.55, 1.03) .10 (.13) 1.11 (.85, 1.44) 
Fatigue -.41 (.17) .67 (.48, .94) -.10 (.12) .90 (.72, 1.14) -.11 (.13) .89 (.69, 1.16) 
Sleep Problems -.33 (.16) .72 (.53, .98) -.20 (.11) .82 (.66, 1.02) -.12 (.12) .89 (.71, 1.12) 
Pain -.41 (.19) .66 (.45, .97) -.13 (.11) .88 (.71, 1.09) -.11 (.12) .89 (.71, 1.13) 
Nausea -.27 (.26) .77 (.46, 1.26) .02 (.13) 1.02 (.80, 1.32) -.19 (.21) .83 (.54, 1.26) 
Lack of Appetite -.24 (.22) .79 (.51, 1.22) .07 (.11) 1.07 (.87, 1.32) .07 (.12) 1.07 (.85, 1.35) 
Emotional Distress -.55 (.30) .58 (.32, 1.03) .05 (.10) 1.05 (.86, 1.29)  -.19 (.14) .83 (.63, 1.09) 
       
Symptom Treatment 
Historye 
      






Fatigue -.81 (1.46) .45 (.03, 7.77) 1.27 (.73) 3.57 (.85, 14.98) .78 (.83) 2.19 (.43, 11.14) 
Sleep Problems -.53 (.96) .59 (.09, 3.90) .43 (.65) 1.54 (.43, 5.47) -.19 (.79) .83 (.18, 3.88) 
Pain .23 (.73) 1.26 (.30, 5.29) .08 (.61) 1.08 (.33, 3.55) -.10 (.68) .91 (.24, 3.45) 
Lack of Appetite -.47 (1.25) .62 (.05, 7.25) -.13 (.89) .88 (.15, 4.99) -1.46 (1.76) .23 (.01, 7.26) 
Note.  The following variables were removed from analyses due to insufficient variance: current cancer treatment of radiation, 
chemoradiation, and clinical trial; symptom treatment history of cough, nausea, and emotional distress; and race/ethnicity.  OR = Odds 
Ratio.  CI = Confidence Interval.  PCOQ = Patient Centered Outcomes Questionnaire.  Class 1 = Low Importance, n = 12.  Class 2 = 
Moderate Importance except for low bronchial symptoms and sleep importance, n = 29.  Class 3 = Moderate Importance except for low 
nausea and emotional distress importance, n = 23.  Class 4 = High Importance, n = 33. 
aNo college education used as the reference group. 
bHousehold income less than $31,000 used as the reference group. 
cTreatment >4 weeks before study completion.   
dTreatment <4 weeks before study completion.   







Table 13 Multinomial Logistic Regression Results using Classes 1 and 2 as Alternative References 
 Class 2 v 1 Class 3 v 1 Class 3 v 2 
  B  (SE) OR (95% CI) B (SE) OR (95% CI) B (SE) OR (95% CI) 
Age .00 (.03) 1.00 (.94, 1.07 ) -.00 (.03) 1.00 (.93, 1.07) -.00 (.03) 1.00 (.94, 1.06) 
       
Gender (Male) .12 (.79) 1.12 (.24, 5.23) -.35 (.80) .70 (.15, 3.39) -.47 (.73) .63 (.15, 2.63) 
       
Married/Living with 
Partner 
.58 (.88) 1.79 (.32, 10.06) -.06 (.83) .94 (.18, 4.83) -.64 (.82) .53 (.11, 2.63) 
       
Employed -.01 (.90) .99 (.17, 5.82) -.58 (1.01) .56 (.08, 4.06) -.57 (.94) .57 (.09, 3.55) 
       
Educationa       
Some College .68 (1.11) 1.98 (.23, 17.40) .73 (1.12) 2.08 (.23, 18.81) .05 (1.00) 1.05 (.15, 7.46) 
Graduated College .02 (1.00) 1.03 (.15, 7.22) -.02 (1.03) .98 (.13, 7.30) -.05 (1.00) .95 (.14, 6.75) 
       
Incomeb       
$31,000 - $99,999 -.11 (1.50) .90 (.05, 16.88) -.17 (1.46) .26 (.02, 3.55) -1.23 (1.18) .29 (.03, 2.92) 
$100,000 or more -.23 (1.57) .79 (.04, 17.03) -.30 (1.53) .17 (.01, 3.08) -1.52 (1.33) .22 (.02, 2.98) 
       
Time Since Diagnosis -.03 (.14) .97 (.73, 1.29) .01 (.14) 1.01 (.77, 1.33) .04 (.13) 1.04 (.81, 1.34) 
       
Functional Status 1.13 (.60) 3.11 (.96, 10.05) 1.66 (.63)* 5.25 (1.52, 18.07) .52 (.43) 1.69 (.73, 3.93) 
       
Number of Medical 
Comorbidities 
.05 (.39) 1.05 (.49, 2.23) .05 (.39) 1.05 (.49, 2.26) .00 (.36) 1.00 (.50, 2.01) 
       
Quality of Life -.35 (.22) .71 (.46, 1.09) -.42 (.23) .66 (.42, 1.03) -.07 (.16) .93 (.68, 1.28) 








      
Surgery -.35 (.95) .70 (.11, 4.51) .30 (.89) 1.35 (.24, 7.70) .65 (.86) 1.92 (.36, 10.30) 
Chemotherapy 1.31 (.84) 3.69 (.72, 18.99) .83 (.82) 2.30 (.47, 11.35) -.48 (.77) .62 (.14, 2.83) 
Radiation .30 (1.07) 1.35 (.17, 10.91) 1.90 (.99) 6.67 (.96, 46.45) 1.60 (.84) 4.93 (.96, 25.41) 
Chemoradiation -.32 (.94) .73 (.12, 4.59) .06 (.91) 1.06 (.18, 6.28) .38 (.87) 1.46 (.27, 7.96) 
Targeted Therapy -.07 (.79) .94 (.20, 4.36) -.03 (.80) .97 (.20, 4.60) .03 (.72) 1.04 (.25, 4.26) 
Immunotherapy -.14 (.79) .87 (.19, 4.05) .51 (.81) 1.66 (.34, 8.11) .65 (.74) 1.92 (.45, 8.16) 
Clinical Trial -.24 (1.08) .79 (.10, 6.54) -.32 (1.12) .72 (.08, 6.47) -.09 (1.07) .92 (.11, 7.48) 
       
Current Cancer 
Treatmentd 
      
Chemotherapy -.52 (.96) .60 (.09, 3.88) -.47 (.96) .62 (.09, 4.12) .04 (.96) 1.04 (.16, 6.79) 
Targeted Therapy .48 (.89) 1.62 (.28, 9.27) .79 (.88) 2.19 (.39, 12.36) .30 (.74) 1.35 (.32, 5.79) 
Immunotherapy .90 (1.01) 2.47 (.34, 18.01) .84 (1.02) 2.32 (.31, 17.18) -.06 (.78) .94 (.20, 4.33) 
       
Usual Severity on PCOQ       
Breathlessness -.06 (.20) .94 (.64, 1.40) .02 (.20) 1.02 (.69, 1.51) .08 (.18) 1.08 (.76, 1.54) 
Cough -.06 (.22) .94 (.62, 1.45) .33 (.20) 1.39 (.94, 2.05) .38 (.17) 1.47 (1.04, 2.07) 
Fatigue .30 (.18) 1.35 (.95, 1.93) .29 (.18) 1.34 (.94, 1.92) -.01 (.15) .99 (.75, 1.32) 
Sleep Problems .13 (.17) 1.14 (.82, 1.58) .22 (.17) 1.24 (.89, 1.72) .09 (.13) 1.09 (.84, 1.41) 
Pain .28 (.20) 1.33 (.89, 1.98) .30 (.20) 1.35 (.91, 2.00) .02 (.13) 1.02 (.79, 1.32) 
Nausea .29 (.26) 1.34 (.80, 2.24) .08 (.30) 1.08 (.60, 1.96) -.21 (.22) .81 (.52, 1.25) 
Lack of Appetite .30 (.23) 1.35 (.87, 2.11) .31 (.23) 1.36 (.87, 2.11) .00 (.12) 1.00 (.80, 1.26) 
Emotional Distress .61 (.31) 1.83 (1.01, 3.33) .37 (.31) 1.44 (.79, 2.62) -.24 (.15) .79 (.59, 1.05) 
       
Symptom Treatment 
Historye 
      
Breathlessness .24 (1.04) 1.28 (.17, 9.81) .58 (1.01) 1.79 (.25, 13.07) .34 (.87) 1.41 (.26, 7.68) 






Sleep Problems .96 (1.01) 2.60 (.36, 18.78) .34 (1.07) 1.40 (.17, 11.32) -.62 (.84) .54 (.10, 2.77) 
Pain -.15 (.80) .86 (.18, 4.11) -.33 (.82) .72 (.15, 3.60) -.17 (.75) .84 (.19, 3.68) 
Lack of Appetite .34 (1.36) 1.41 (.10, 20.04) -.99 (1.99) .37 (.01, 18.47) -1.33 (1.86) .27 (.01, 10.11) 
Note.  The following variables were removed from analyses due to insufficient variance: current cancer treatment of radiation, 
chemoradiation, and clinical trial; symptom treatment history of cough, nausea, and emotional distress; and race/ethnicity.  OR = Odds 
Ratio.  CI = Confidence Interval.  PCOQ = Patient Centered Outcomes Questionnaire.  Class 1 = Low Importance, n = 12.  Class 2 = 
Moderate Importance except for low bronchial symptoms and sleep importance, n = 29.  Class 3 = Moderate Importance except for 
low nausea and emotional distress importance, n = 23.  Class 4 = High Importance, n = 33. 
aNo college education used as the reference group. 
bHousehold income less than $31,000 used as the reference group. 
cTreatment >4 weeks before study completion.   
dTreatment <4 weeks before study completion.   



























Figure 1.  Study procedures flow chart. 
IU = Indiana University. 
IU Simon Cancer Center records screened to identify 
potentially eligible patients 
Oncologists contacted to verify 
eligibility 
Potentially eligible patients mailed an information 
packet (N = 176) 
Could not be reached by phone  
(N = 27) 
~1 week after mailing, research assistant called patients to administer cognitive screener and 
obtain verbal informed consent (N = 176) 
Refusers could provide 
reason for refusal, age, race, 
and gender (N = 21) 
Within 3 days of 
consenting, patients were 
sent paper or online survey 
(N = 111) 
If survey not received within ~2 weeks, spoke 
to patient up to 5 times to remind them to 
complete survey 
Patients were mailed $25 Target gift 
card when completed survey was 
received (N = 103) 
Did not meet eligibility 
criteria (N = 17)  
Patient found to be ineligible after 
study completion (N = 1) 






































Class 1: Low Importance, 12%
Class 2: Moderate Importance except for low bronchial symptoms and sleep importance, 30%
Class 3: Moderate Importance except for low nausea and emotional distress importance, 24%




6-Item Cognitive Screener 
 
I would like to ask you some questions that ask you to use your memory. I am going to name 
three objects. Please wait until I say all three words, then repeat them. Remember what they are 
because I am going to ask you to name them again in a few minutes. Please repeat these words 
for me: APPLE—TABLE—PENNY. 
(Interviewer may repeat words up to 3 times if necessary. Repetition is not scored.) 
Did patient correctly repeat all three words?             YES              NO 
 
If NO, patient is INELIGIBLE. 
If YES, proceed below: 
 
 CORRECT INCORRECT 
1) What year is this?             1 0 
2) What month is this?  1 0 
3) What day of the week is it today?  1 0 
4) What were the three objects I asked you to remember?  
       4a)   APPLE 1 0 
       4b)   TABLE 1 0 
       4c)   PENNY 1 0 
 
 
Add correct answers for TOTAL score: ___________       
 
score ≤3 = INELIGIBLE  





1. What ethnicity do you consider yourself to be? 
 ___Hispanic or Latino/a  
 ___non-Hispanic or Latino/a  
 
2. What race do you consider yourself to be? Check all that apply.  
 White 
 Black or African American 
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 Asian American 
 Native American or Alaska Native   
 Native Hawaiian or Other Pacific Islander  
 Other (please specify): _________________________  
 
3. What is your marital status? 







4. What is your current employment status? 
___Employed full-time 




___Unemployed, looking for work  
___Unemployed due to disability 
___Other (please specify): ______________________________ 
 
5. What is the highest grade or year of school you completed? 
___Never attended school or only attended kindergarten  
___Grades 1 through 8 (Elementary)  
___Grades 9 through 11 (Some high school)  
___Grade 12 or GED (High school graduate)  
___College 1 year to 3 years (Some college or technical school)  
___College 4 years or more (College graduate)  
___Graduate school (Master’s degree, Doctorate, etc.)  
 
 
6. What is the annual, combined income range for all family members in your household?  
___Less than $21,000  
___$21,000 - $30,999  
___$31,000 - $50,999  
___$51,000 - $99,999  
___$100,000 or more 
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(1) Age: _____ 
(2) Gender:   Male    Female 
 
 
Patient’s Cancer History: 
 
(1)  stage IIIB non-small cell lung cancer; date of Diagnosis: ____/____/_____ 
(2)  stage IIIC non-small cell lung cancer; date of Diagnosis: ____/____/_____ 
(3)  stage IV non-small cell lung cancer; date of Diagnosis: ____/____/_____ 
(4)  extensive stage small cell lung cancer; date of Diagnosis: ____/____/_____ 
 




 Radiation   
 Chemoradiation (concurrent chemotherapy and radiation)   
 Targeted therapy 
 Immunotherapy 
 Other: ___________  
 
 
Treatments for Cancer (check all that are current treatments; last dose given < 4 weeks ago):    
  
 Chemotherapy 
 Radiation   
 Chemoradiation (concurrent chemotherapy and radiation)   
 Targeted therapy 
 Immunotherapy 







Comorbid Medical Conditions 
1. Besides cancer, indicate all medical conditions that a doctor or other health care worker has 
diagnosed you with or treated you for during the past 3 years. Check all that apply.  
 Asthma, emphysema, or chronic bronchitis  
 High blood pressure or hypertension  
 High blood sugar or diabetes  
 Arthritis or rheumatism (inflammation of the joints) 
 Angina, heart failure, or other types of heart disease  
 Strokes, seizures, Parkinson's disease, or other neurological condition  
 Liver disease  
 Kidney or renal disease  
 
Performance Status of the Patient Generated Subjective Global Assessment (PG-SGA) 
2. Over the last month, I would generally rate my activity as: 
 Normal with no limitations 
 Not my normal self, but able to be up and about with fairly normal activities 
 Not feeling up to most things, but in bed or chair less than half the day 
 Able to do little activity and spend most of the day in bed or chair 
 Pretty much bedridden, rarely out of bed 
 
Symptom Treatment History 
Please indicate any symptoms for which you have RECEIVED TREATMENT in the past 3 months, 
including over-the-counter or prescribed medication, oxygen, psychotherapy/counseling, or other 
treatments.  Check all that apply. 
 breathlessness 
 cough      
 fatigue (or tiredness)     
 sleep problems    
 pain      
 nausea    
 lack of appetite     





PROMIS Pain Intensity 
 
In the past 7 days… Had no pain Mild Moderate Severe Very severe 
1 













How intense was your average 











 No pain Mild Moderate Severe Very severe 
3 














PROMIS Sleep Problems 
 
In the past 7 days… Not at all A little bit Somewhat Quite a bit Very much 

































 Very poor Poor Fair Good Very good 














During the past 7 days… Not at all A little bit Somewhat Quite a bit Very 
much 












I had trouble starting things 









































PROMIS Anxiety and Depression 
 
In the past 7 days… Never Rarely Sometimes Often Always 











I found it hard to focus on anything 















































































MSAS Shortness of Breath 
 
 YES NO 
1 
During the past week, did you 





If no, please skip questions 2-4 and go to the next set of questions. 
 
 Rarely Occasionally Frequently Almost constantly 









 Slight Moderate Severe Very severe 































 YES NO 
1 
During the past week, did you 





If no, please skip questions 2-4 and go to the next set of questions. 
 
 Rarely Occasionally Frequently Almost constantly 









 Slight Moderate Severe Very severe 









 Not at all A little bit Somewhat Quite a bit Very much 
4 














 YES NO 
1 






If no, please skip questions 2-4 and go to the next set of questions. 
 
 Rarely Occasionally Frequently Almost constantly 









 Slight Moderate Severe Very severe 









 Not at all A little bit Somewhat Quite a bit Very much 
4 
















MSAS Lack of Appetite 
 
 YES NO 
1 
During the past week, did 





If no, please skip questions 2-4 and go to the next set of questions. 
 
 Rarely Occasionally Frequently Almost constantly 









 Slight Moderate Severe Very severe 









 Not at all A little bit Somewhat Quite a bit Very much 
4 


















Patient Centered Outcomes Questionnaire 
 
Please rate your usual level of each symptom during the past week, whether or not you think it was related to cancer, its treatment, 
or other medical conditions. 
 
Question Set #1: Breathlessness None Moderate 
Worst  
imaginable                
1 
During the past week, what was your usual level of 
breathlessness? 
0 1 2 3 4 5 6 7 8 9 10 
If 0, please skip questions 2-3 and go to the next set of questions. 
 
It makes sense that patients want their symptom treatment to result 
in desired or acceptable outcomes. Unfortunately, available 
treatments for symptoms do not always produce desired outcomes. None Moderate 
Worst  
imaginable                
2 
What level of breathlessness would be acceptable to you if you 
were to receive treatment for breathlessness?  









important                
3 
How important is it for you to see improvement in your level 
of breathlessness? 








Question Set #2: Cough None Moderate 
Worst  
imaginable                
1 During the past week, what was your usual level of cough? 0 1 2 3 4 5 6 7 8 9 10 
If 0, please skip questions 2-3 and go to the next set of questions. 
 
It makes sense that patients want their symptom treatment to result 
in desired or acceptable outcomes. Unfortunately, available 
treatments for symptoms do not always produce desired outcomes. None Moderate 
Worst  
imaginable                
2 
What level of cough would be acceptable to you if you were to 
receive treatment for cough?  









important                
3 
How important is it for you to see improvement in your level 
of cough? 








Question Set #3: Fatigue (or tiredness) None Moderate 
Worst  
imaginable                
1 
During the past week, what was your usual level of fatigue (or 
tiredness)? 
0 1 2 3 4 5 6 7 8 9 10 
If 0, please skip questions 2-3 and go to the next set of questions. 
 
It makes sense that patients want their symptom treatment to result 
in desired or acceptable outcomes. Unfortunately, available 
treatments for symptoms do not always produce desired outcomes. None Moderate 
Worst  
imaginable                
2 
What level of fatigue (or tiredness) would be acceptable to 
you if you were to receive treatment for fatigue (or tiredness)?  









important                
3 
How important is it for you to see improvement in your level 
of fatigue (or tiredness)? 








Question Set #4: Sleep problems None Moderate 
Worst  
imaginable                
1 
During the past week, what was your usual level of sleep 
problems? 
0 1 2 3 4 5 6 7 8 9 10 
If 0, please skip questions 2-3 and go to the next set of questions. 
 
It makes sense that patients want their symptom treatment to result in 
desired or acceptable outcomes. Unfortunately, available treatments 
for symptoms do not always produce desired outcomes. None Moderate 
Worst  
imaginable                
2 
What level of sleep problems would be acceptable to you if you 
were to receive treatment for sleep problems?  









important                
3 
How important is it for you to see improvement in your level of 
sleep problems? 








Question Set #5: Pain None Moderate 
Worst  
imaginable                
1 During the past week, what was your usual level of pain? 0 1 2 3 4 5 6 7 8 9 10 
If 0, please skip questions 2-3 and go to the next set of questions. 
 
It makes sense that patients want their symptom treatment to 
result in desired or acceptable outcomes. Unfortunately, available 
treatments for symptoms do not always produce desired 
outcomes. None Moderate 
Worst  
imaginable                
2 
What level of pain would be acceptable to you if you were to 
receive treatment for pain?  









important                
3 
How important is it for you to see improvement in your level 
of pain? 








Question Set #6: Nausea None Moderate 
Worst  
imaginable                
1 During the past week, what was your usual level of nausea? 0 1 2 3 4 5 6 7 8 9 10 
If 0, please skip questions 2-3 and go to the next set of questions. 
 
It makes sense that patients want their symptom treatment to result in 
desired or acceptable outcomes. Unfortunately, available treatments 
for symptoms do not always produce desired outcomes. None Moderate 
Worst  
imaginable                
2 
What level of nausea would be acceptable to you if you were to 
receive treatment for nausea?  









important                
3 
How important is it for you to see improvement in your level of 
nausea? 








Question Set #7: Lack of appetite None Moderate 
Worst  
imaginable                
1 
During the past week, what was your usual level of lack of 
appetite? 
0 1 2 3 4 5 6 7 8 9 10 
If 0, please skip questions 2-3 and go to the next set of questions. 
 
It makes sense that patients want their symptom treatment to result in 
desired or acceptable outcomes. Unfortunately, available treatments 
for symptoms do not always produce desired outcomes. None Moderate 
Worst  
imaginable                
2 
What level of lack of appetite would be acceptable to you if you 
were to receive treatment for lack of appetite?  









important                
3 
How important is it for you to see improvement in your level of 
lack of appetite? 








Question Set #8: Emotional distress None Moderate 
Worst  
imaginable                
1 
During the past week, what was your usual level of emotional 
distress? 
0 1 2 3 4 5 6 7 8 9 10 
If 0, please skip questions 2-3 and go to the next set of questions. 
 
It makes sense that patients want their symptom treatment to result 
in desired or acceptable outcomes. Unfortunately, available 
treatments for symptoms do not always produce desired outcomes. None Moderate 
Worst  
imaginable                
2 
What level of emotional distress would be acceptable to you if 
you were to receive treatment for emotional distress?  









important                
3 
How important is it for you to see improvement in your level 
of emotional distress? 
0 1 2 3 4 5 6 7 8 9 10 
 
